Edison issues review on The Biotech Growth Trust

RNS Number : 4130Y

Biotech Growth Trust PLC (The)

06 September 2022

 

London, UK, 6 September 2022

Edison issues review on The Biotech Growth Trust (BIOG)

The Biotech Growth Trust (BIOG) is managed by global healthcare specialist OrbiMed Capital. Despite a reversal in the trust's relative performance following a very successful FY21 (ending 31 March 2021), manager Geoff Hsu is continuing to favour smaller-cap, emerging biotech stocks, as he says these companies are where the bulk of industry innovation occurs, and this is the primary driver of the biotech sector's long-term positive performance. The manager believes that the latest drawdown in biotech stocks, which is unprecedented in both magnitude and duration, has led to a very large disconnect between favourable industry fundamentals and very low biotech company valuations. Over the last year, BIOG's portfolio has become increasingly concentrated as Hsu and his team are focusing more on their highest-conviction investments.

BIOG's valuation has been volatile since early 2021, which coincides with the trust's period of relative underperformance. Its 8.3% discount to cum-income NAV compares with a 4.0% to 4.9% range of average discounts over the last one, three, five and 10 years. If BIOG can build on its very long-term record of outperformance, there is potential for the trust to be afforded a higher valuation. 

Click here to view the full report or here to sign up to receive research as it is published.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: E dison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner [phone] [e-mail]

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn  www.linkedin.com/company/edison-group-/

Twitter   www.twitter.com/Edison_Inv_Res

YouTube  www.youtube.com/edisonitv

 

END

 

 

NRAUPUQWBUPPUMQ